Conexeu Sciences Inc. (NASDAQ:CNXU – Get Free Report) Director Lynn Sebastian Purcell acquired 202,500 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $162,000.00. Following the acquisition, the director directly owned 2,734,240 shares of the company’s stock, valued at $2,187,392. The trade was a 8.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Conexeu Sciences Trading Down 13.4%
NASDAQ CNXU traded down $1.63 during trading on Tuesday, reaching $10.55. The company’s stock had a trading volume of 51,155 shares, compared to its average volume of 87,755. Conexeu Sciences Inc. has a 1-year low of $9.60 and a 1-year high of $18.79.
Analysts Set New Price Targets
A number of brokerages have weighed in on CNXU. HC Wainwright started coverage on Conexeu Sciences in a research report on Monday. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.00.
Conexeu Sciences Company Profile
Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.
Featured Stories
- Five stocks we like better than Conexeu Sciences
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Conexeu Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conexeu Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
